Lund, Sweden, 2015-05-25 08:52 CEST (GLOBE NEWSWIRE) --
A new study of the imaging biomarker Bone Scan Index (BSI) has qualified for oral presentation at the 2015 SNMMI (Society of Nuclear Medicine and Molecular Imaging) annual meeting, 6-10th of June, in Baltimore, USA. The congress is regarded as the leading congress within nuclear medicine, attracting 4 000 world-leading experts.
The SNMMI-congress brings together experts within molecular imaging and nuclear medicine with leading radiologists, radio-pharmacists, scientists, technicians and medical laboratory scientists from prominent medical and academic institutions and centres world-wide.
“For the first time a BSI-study will be presented at this, the largest and most renowned congress for nuclear medicine professionals. The majority of participants will be US nuclear medicine physicists, that’s why this presentation is instrumental in generating interest and spreading knowledge about BSI and the software EXINI boneBSI to the US market”, comments Magnus Aurell, CEO, EXINI Diagnostics AB.
Details on the BSI-presentation:
”Analytical validation of automated Bone Scan index (BSI) as an imaging biomarker in patients with metastatic prostate cancer (mPC)” by Aseem Anand, Michael J Morris, David Minarik, Anders Bjartell, and Lars Edenbrandt at Memorial Sloan Kettering Cancer Center, New York, US, and Lund University, Malmö, Sweden.
For details on the presentation, please visit: http://snmmi.staging.m.eventsential.org/Sessions/Details/78063
More on Bone Scan Index (BSI):
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate or breast cancer.
Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI boneBSI is the only software capable of calculating the BSI-value.
www.bonescanindex.org
www.exini.com/software/exini-bone-bsi/
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
